Sputnik V vaccine shows 92% efficacy, says Russia

Russias National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund on Wednesday announced that the Sputnik V vaccine the worlds first registered vaccine against coronavirus created on the wellstudied platform of human adenoviral vectors demonstrated 92 per cent efficacyCurrently Sputnik V Phase III clinical trials are approved and are undergoing in Belarus the UAE Venezuela and other countries as well as Phase IIIII in India A separate detailed study of the vaccines safety and immunogenicity for elderly people is also being conductedThe confirmation is based on the first interim data from the largest doubleblind randomized placebocontrolled Phase III clinical trials in Russia involving 40000 volunteers The trials evaluated efficacy among over 16000 volunteers who received the vaccine or placebo 21 days after the first injectionAs a result of a statistical analysis of 20 confirmed cases of coronavirus the case split between vaccinated individuals and those who received the placebo indicates that the Sputnik V vaccine had an efficacy rate of 92 per cent after the second doseSeparately in September the vaccine was first administered to a group of volunteers from the red zones of the Russian hospitals The observation of additional 10000 vaccinated volunteers representing medics and other highrisk groups under the civil use of the vaccine out of clinical trials also confirmed the vaccines efficacy rate of over 90 per centThe data received will be published by Gamaleya Center researchers in one of the worlds leading peerreviewed medical academic journals following an independent valuation of the data by leading epidemiology experts Following the completion of Phase III clinical trials of the Sputnik V vaccine Gamaleya Center will provide access to the full clinical trial reportAs of November 11 as part of the clinical trials in Russias 29 medical centres more than 20000 volunteers were vaccinated with the first dose and over 16000 volunteers with the first and the second dose of the vaccineIn addition as of November 11 no unexpected adverse events were identified as part of the research Some of those vaccinated had shortterm minor adverse events such as pain at the injection site flulike syndrome including fever weakness fatigue and headacheDuring the clinical trials the safety of the vaccine is constantly being monitored information is analysed by the Independent Monitoring Committee comprising of leading Russian scientists Collection quality control and data processing is conducted in line with the ICH GCP standards and involves active participation of Moscows Health Department and Crocus Medical the contract research organization CROObservation of the study participants will continue for six months after which the final report will be presented The research data will be provided by RDIF to the national regulators of countries interested in purchasing the Russian vaccine in order to streamline the registration processMikhail Murashko Minister of Health of the Russian Federation said that the use of the vaccine and the results of clinical trials demonstrate that it is an efficient solution to stop the spread of the coronavirus infection a preventive healthcare tool and this is the most successful path to defeat the pandemicAlexander Gintsburg Gamaleya Center Director The publication of the interim results of the postregistration clinical trials that convincingly demonstrate Sputnik V vaccines efficacy gives way to mass vaccination in Russia against Covid19 in the coming weeks Thanks to the production scale up at new manufacturing sites Sputnik V vaccine will soon be available for a wider population This will break the current trend and lead to an eventual decrease in Covid19 infection rates first in Russia then globallyDenis Logunov Gamaleya Center Deputy Director said that positive interim results of Phase III give reasons to expect a successful outcome of Sputnik V clinical trials We will continue to process and analyse all the data and look to the future with optimism expecting that results of our work will help end the pandemic soonerKirill Dmitriev CEO Russian Direct Investment Fund Sputnik V is the first registered vaccine against Covid19 in the world the vaccine is based on a safe and effective platform of human adenoviral vectors More and more countries are recognising the human adenoviral vector platform and plan to include these vaccines as the most studied and known in their respective national vaccine portfolio I would also like to stress the importance of international cooperation and close partnership among vaccinedeveloping statesHe added Vaccines should be above politics The world needs a diversified portfolio of highquality vaccines with Sputnik V based on the welltested human adenoviral vector platform being an important element of itThe safety of vaccines based on human adenoviruses was confirmed in more than 75 international publications and more than 250 clinical trials conducted during the past two decades while the history of use of human adenoviruses in vaccine development started in 1953Adenovirus vectors are genetically modified viruses of the regular flu that cannot reproduce in a human body When Sputnik V vaccine is used the coronavirus itself does not enter the body as the vaccine only contains genetic information about part of its outer protein coat the socalled spikes forming its crown This completely eliminates the possibility of getting infected as a result of vaccination while also causing the bodys stable immune responseOn September 4 The Lancet one of worlds leading medical journals published a research paper on the results of Phase I and Phase II clinical trials of the vaccine that showed no serious adverse events and an effective immune response of those vaccinatedRequests for more than 12 billion doses of Sputnik V vaccine came from over 50 countries The vaccine supplies for the global market will be produced by RDIFs international partners in India Brazil China South Korea and other countriesThe existing RDIF contracts with international partners enable the production of 500 million doses of the Sputnik V vaccine outside Russia annually RDIF is now considering additional requests from a number of countries and companies to further increase its foreign production capacitiesOn August 11 the Sputnik V vaccine developed by the Gamaleya Center was registered by Russias Health Ministry and became the worlds first registered vaccine against Covid19Keep scrolling to read more newsCatch up on all the latest Crime National International and Hatke news here Also download the new midday Android and iOS apps to get latest updates MidDay is now on Telegram Click here to join our channel middayinfomedialtd and stay updated with the latest newsThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever